D P Maher1, W Wong2, P F White3, R McKenna2, H Rosner2, B Shamloo2, C Louy2, R Wender2, R Yumul4, V Zhang2. 1. Department of Anaesthesiology, Cedars Sinai Medical Center, Los Angeles, CA, USA dermot.maher@cshs.org. 2. Department of Anaesthesiology, Cedars Sinai Medical Center, Los Angeles, CA, USA. 3. Department of Anaesthesiology, Cedars Sinai Medical Center, Los Angeles, CA, USA Instituto Ortopedico Rizzoli, University of Bologna, Bologna, Italy. 4. Department of Anaesthesiology, Cedars Sinai Medical Center, Los Angeles, CA, USA David Geffen School of Medicine-UCLA, Los Angeles, CA, USA.
Abstract
BACKGROUND: Evidence suggests that opioid-sparing anaesthetic techniques might be associated with increased cancer-free postoperative survival. This could be related to suppression of natural killer cells by opioid analgesics in the perioperative period. This retrospective analysis tested the hypothesis that greater opioid use in the postoperative period is associated with a higher incidence of recurrences after surgery for lung cancer. METHODS: The medical records of 99 consecutive patients who underwent video-assisted thoracoscopic surgery with lobectomy for Stage I or IIa biopsy-proven non-small-cell lung cancer (NSCLC) were reviewed. Perioperative information including patient characteristics, laboratory data, and surgical, anaesthetic, nursing, and pharmacy reports were collected. Doses of opioids administered intra-operatively and for the first 96 h after operation were converted into equianalgesic doses of oral morphine using a standard conversion table. Data were then compared with the National Cancer Registry's incidence of disease-free survival for 5 yr. RESULTS: A total of 99 patients with similar characteristics were included in the final analysis, 73 of whom were NSCLC recurrence-free at 5 yr and 26 had NSCLC recurrence within 5 yr. Total opioid dose during the 96 h postoperative period was 124 (101) mg of morphine equivalents in the cancer-free group and 232 mg (355) mg in the recurrence group (P=0.02). CONCLUSIONS: This retrospective analysis suggests an association between increased doses of opioids during the initial 96 h postoperative period with a higher recurrence rate of NSCLC within 5 yr.
BACKGROUND: Evidence suggests that opioid-sparing anaesthetic techniques might be associated with increased cancer-free postoperative survival. This could be related to suppression of natural killer cells by opioid analgesics in the perioperative period. This retrospective analysis tested the hypothesis that greater opioid use in the postoperative period is associated with a higher incidence of recurrences after surgery for lung cancer. METHODS: The medical records of 99 consecutive patients who underwent video-assisted thoracoscopic surgery with lobectomy for Stage I or IIa biopsy-proven non-small-cell lung cancer (NSCLC) were reviewed. Perioperative information including patient characteristics, laboratory data, and surgical, anaesthetic, nursing, and pharmacy reports were collected. Doses of opioids administered intra-operatively and for the first 96 h after operation were converted into equianalgesic doses of oral morphine using a standard conversion table. Data were then compared with the National Cancer Registry's incidence of disease-free survival for 5 yr. RESULTS: A total of 99 patients with similar characteristics were included in the final analysis, 73 of whom were NSCLC recurrence-free at 5 yr and 26 had NSCLC recurrence within 5 yr. Total opioid dose during the 96 h postoperative period was 124 (101) mg of morphine equivalents in the cancer-free group and 232 mg (355) mg in the recurrence group (P=0.02). CONCLUSIONS: This retrospective analysis suggests an association between increased doses of opioids during the initial 96 h postoperative period with a higher recurrence rate of NSCLC within 5 yr.
Authors: Deirdre P Cronin-Fenton; Uffe Heide-Jørgensen; Thomas P Ahern; Timothy L Lash; Peer M Christiansen; Bent Ejlertsen; Per Sjøgren; Henrik Kehlet; Henrik T Sørensen Journal: Cancer Date: 2015-07-24 Impact factor: 6.860
Authors: Jonathan B Yuval; Jasme Lee; Fan Wu; Hannah M Thompson; Floris S Verheij; Hersh V Gupta; Takeshi Irie; Joseph R Scarpa; Patrick J McCormick; J Joshua Smith; Jinru Shia; Martin R Weiser; Francisco Sánchez-Vega; Kay See Tan; Gregory W Fischer; Julio Garcia-Aguilar; Joshua S Mincer Journal: Br J Anaesth Date: 2022-06-17 Impact factor: 11.719
Authors: A Carmona-Bayonas; P Jiménez-Fonseca; E Castañón; A Ramchandani-Vaswani; R Sánchez-Bayona; A Custodio; D Calvo-Temprano; J A Virizuela Journal: Clin Transl Oncol Date: 2016-07-21 Impact factor: 3.405
Authors: James G Connolly; Kay See Tan; Brooke Mastrogiacomo; Joseph Dycoco; Raul Caso; Gregory D Jones; Patrick J McCormick; Francisco Sanchez-Vega; Takeshi Irie; Joseph R Scarpa; Hersh V Gupta; Prasad S Adusumilli; Gaetano Rocco; James M Isbell; Matthew J Bott; Gregory W Fischer; David R Jones; Joshua S Mincer Journal: Br J Anaesth Date: 2021-07 Impact factor: 11.719